Treatment outcomes among HIV-1 and HIV-2 infected children initiating antiretroviral therapy in a concentrated low prevalence setting in West Africa

BMC Pediatrics

Volumn 12, Issue , 2012, Pages

  Okomo, Uduak ^a   Togun, Toyin ^a   Oko, Francis ^a   Peterson, Kevin ^a,b   Townend, John ^a   Peterson, Ingrid ^c   Jaye, Assan ^a,d  

^a MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^b INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^c Mailman School of Public Health Columbia University ^*  (United States)

^d UNIVERSITÉ CHEIKH ANTA DIOP   (Senegal)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; STAVUDINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE; LOPINAVIR; LOPINAVIR RITONAVIR DRUG COMBINATION; LOPINAVIR-RITONAVIR DRUG COMBINATION; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

AGE; ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD; FEMALE; GAMBIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MAJOR CLINICAL STUDY; MALE; TREATMENT OUTCOME; VIRUS LOAD; ADOLESCENT; CLINICAL TRIAL; COHORT ANALYSIS; DRUG COMBINATION; FOLLOW UP; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; KAPLAN MEIER METHOD; MORTALITY; PRESCHOOL CHILD; STATISTICS; VIROLOGY;

ADOLESCENT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; GAMBIA; HIV INFECTIONS; HIV-1; HIV-2; HUMANS; INFANT; KAPLAN-MEIER ESTIMATE; LAMIVUDINE; LOPINAVIR; MALE; NEVIRAPINE; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; TREATMENT OUTCOME; VIRAL LOAD; ZIDOVUDINE;

EID: 84864503450     PISSN: None     EISSN: 14712431     Source Type: Journal    
DOI: 10.1186/1471-2431-12-95     Document Type: Article

References (40)

1. WHO, UNAIDS, UNICEF Towards Universal Access: Scaling up priority HIV/AIDS interventions in the health sector. Progress Report 2010 2010, World Health Organization, Geneva, WHO, UNAIDS, UNICEF.
2. National Sentinel Surveillance Working Group National Sentinel Surveillance Bulletin 2008 2008, Department of State for Health (DoSH), Banjul, The Gambia, National Sentinel Surveillance Working Group.
3. Clavel F, Mansinho K, Chamaret S, Guetard D, Favier V, Nina J, Santos-Ferreira MO, Champalimaud JL, Montagnier L. Human immunodeficiency virus type 2 infection associated with AIDS in West Africa. N Engl J Med 1987, 316:1180-1185. 10.1056/NEJM198705073161903, 3472076.
4. Marlink R, Kanki P, Thior I, Travers K, Eisen G, Siby T, Traore I, Hsieh CC, Dia MC, Gueye EH, et al. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science 1994, 265:1587-1590. 10.1126/science.7915856, 7915856.
5. Morgan G, Wilkins HA, Pepin J, Jobe O, Brewster D, Whittle H. AIDS following mother-to-child transmission of HIV-2. AIDS 1990, 4:879-882. 10.1097/00002030-199009000-00008, 1979226.
6. van der Loeff MF S, Jaffar S, Aveika AA, Sabally S, Corrah T, Harding E, Alabi A, Bayang A, Ariyoshi K, Whittle HC. Mortality of HIV-1, HIV-2 and HIV-1/HIV-2 dually infected patients in a clinic-based cohort in The Gambia. AIDS 2002, 16:1775-1783. 10.1097/00002030-200209060-00010, 12218389.
7. O'Donovan D, Ariyoshi K, Milligan P, Ota M, Yamuah L, Sarge-Njie R, Whittle H. Maternal plasma viral RNA levels determine marked differences in mother-to-child transmission rates of HIV-1 and HIV-2 in The Gambia MRC/Gambia Government/University College London Medical School working group on mother-child transmission of HIV. AIDS 2000, 14:441-448. 10.1097/00002030-200003100-00019, 10770548.
8. Adjorlolo-Johnson G, DeCock K, Ehounou E, et al. Prospective comparison of mother-to-child transmision of HIV-1 and HIV-2 in Abidjan, Ivory Coast. JAMA 1994, 272:462-466. 10.1001/jama.1994.03520060062033, 8040982.
9. Andreasson PA, Dias F, Naucler A, Andersson S, Biberfeld G. A prospective study of vertical transmission of HIV-2 in Bissau, Guinea-Bissau. AIDS 1993, 7:989-993. 10.1097/00002030-199307000-00013, 8357558.
10. Burgard M, Jasseron C, Matheron S, Damond F, Hamrene K, Blanche S, Faye A, Rouzioux C, Warszawski J, Mandelbro L. Mother-to-child transmission of HIV-2 infection from 1986 to 2007 in the ANRS French Perinatal Cohort EPF-CO1. Clin Infect Dis 2010, 51:833-843. 10.1086/656284, 20804413.
11. UNICEF Unite for Children, Unite Against AIDS. Children and AIDS: The Fourth Stocktaking Report 2009, UNICEF, Geneva, UNICEF.
12. Adje-Toure C, Hanson DL, Talla-Nzussouo N, Borget MY, Kouadio LY, Tossou O, Fassinou P, Bissagnene E, Kadio A, Nolan ML, Nkengasong JN. Virologic and immunologic response to antiretroviral therapy and predictors of HIV type 1 drug resistance in children receiving treatment in Abidjan, Cote d'Ivoire. AIDS Res Hum Retroviruses 2008, 24:911-917. 10.1089/aid.2007.0264, 18593341.
13. Diack MA, Signate Sy H, Diagne Gueye NR, Ba A, Sylla A, Diouf S, Diagne I, Sarr M, Sow HD. Epidemiological and clinical aspects of paediatric HIV infections in Albert-Royer Paediatric Hospital Dakar, Senegal. Archives of Pediatrics 2005, 12:404-409.
14. Elise A, France AM, Louise WM, Bata D, François R, Roger S, Philippe M. Assessment of Adherence to Highly Active Antiretroviral Therapy in a Cohort of African HIV-Infected Children in Abidjan, Cote d'Ivoire. Journal of Acquired Immune Deficiency Syndromes 2005, 40:498-500. 10.1097/01.qai.0000168180.76405.5f, 16280708.
15. Fassinou P, Elenga N, Rouet F, Laguide R, Kouakoussui KA, Timite M, Blanche S, Msellati P. Highly active antiretroviral therapies among HIV-1-infected children in Abidjan, Cote d'Ivoire. AIDS 2004, 18:1905-1913. 10.1097/00002030-200409240-00006, 15353976.
16. Ota MO, O'Donovan D, Alabi AS, Milligan P, Yamuah LK, N'Gom PT, Harding E, Ariyoshi K, Wilkins A, Whittle HC. Maternal HIV-1 and HIV-2 infection and child survival in The Gambia. AIDS 2000, 14:435-439. 10.1097/00002030-200003100-00018, 10770547.
17. van der Loeff MF S, Hansmann A, Awasana AA, Ota MO, O'Donovan D, Sarge-Njie R, Ariyoshi K, Milligan P, Whittle H. Survival of HIV-1 and HIV-2 perinatally infected children in The Gambia. AIDS 2003, 17:2389-2394. 10.1097/00002030-200311070-00015, 14571192.
18. Gottlieb GS, Eholié S-P, Nkengasong JN, Jallow S, Rowland-Jones S, Whittle HC, Sow PS. A call for randomized controlled trials of antiretroviral therapy for HIV-2 infection in West Africa. AIDS 2008, 22:2069-2072. 10.1097/QAD.0b013e32830edd44, 2635911, 18832869.
19. WHO Scaling up antitertiviral therapy in resource limited settings: Treatment guidelines for a public health approach (2003 Revision) 2004, World Health Organization, Geneva, WHO.
20. WHO Antiretroviral therapy for HIV infection in infants and children: towards universal access recommendations for a public health approach 2006, World Health Organization, Geneva, WHO.
21. Department of State for Health The Gambia: Antiretroviral Therapy: A manual for health service providers 2004, New Type Press, Banjul, Department of State for Health.
22. UNAIDS, WHO Provisional WHO/UNAIDS Secretariat recommendations on the use of cotrimoxazole prophylaxis in adults and children living with HIV/AIDS in Africa 2000, Joint United Nations Program on HIV/AIDS and World Health Organization, Geneva, UNAIDS, WHO.
23. WHO Guidelines on co-trimoxazole prophylaxis for HIV-related infections among children, adolescents and adults: Recommendations for a public health approach 2006, World Health Organization, Geneva, WHO.
24. Damond F, Benard A, Ruelle J, Alabi A, Kupfer B, Gomes P, Rodes B, Albert J, Boni J, Garson J, et al. Quality control assessment of human immunodeficiency virus type 2 (HIV-2) viral load quantification assays: results from an international collaboration on HIV-2 infection in 2006. J Clin Microbiol 2008, 46:2088-2091. 10.1128/JCM.00126-08, 2446851, 18434556.
25. Sutcliffe CG, van Dijk JH, Bolton C, Persaud D, Moss WJ. Effectiveness of antiretroviral therapy among HIV-infected children in sub-Saharan Africa. Lancet Infect Dis 2008, 8:477-489. 10.1016/S1473-3099(08)70180-4, 18652994.
26. Denny T, Yogev R, Gelman R, et al. Lymphocyte subsets in healthy children during the first 5 years of life. JAMA 1992, 267:1484-1488. 10.1001/jama.1992.03480110060034, 1347086.
27. Resino S, Resino R, Leon JA, Bellon JM, Martin-Fontelos P, Ramos JT, Gurbindo-Gutierrez D, de Jose MI, Ciria L, Munoz-Fernandez MA. Impact of long-term viral suppression in CD4+ recovery of HIV-children on Highly Active Antiretroviral Therapy. BMC Infect Dis 2006, 6:10. 10.1186/1471-2334-6-10, 1403782, 16433913.
28. Tarwater PM, Margolick JB, Jin J, Phair JP, Detels R, Rinaldo C, Giorgi J, Munoz A. Increase and plateau of CD4 T-cell counts in the 3(1/2) years after initiation of potent antiretroviral therapy. J Acquir Immune Defic Syndr 2001, 27:168-175.
29. Bolton-Moore C, Mubiana-Mbewe M, Cantrell RA, Chintu N, Stringer EM, Chi BH, Sinkala M, Kankasa C, Wilson CM, Wilfert CM, et al. Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia. JAMA 2007, 298:1888-1899. 10.1001/jama.298.16.1888, 17954540.
30. Wamalwa DC, Farquhar C, Obimbo EM, Selig S, Mbori-Ngacha DA, Richardson BA, Overbaugh J, Emery S, Wariua G, Gichuhi C, et al. Early Response to Highly Active Antiretroviral Therapy in HIV-1-Infected Kenyan Children. J Acquir Immune Defic Syndr 2007, 45:311-317. 3380073, 17356470.
31. Reddi A, Leeper SC, Grobler AC, Geddes R, France KH, Dorse GL, Vlok WJ, Mntambo M, Thomas M, Nixon K, et al. Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal. South Africa. BMC Pediatr 2007, 7:13.
32. Fenner L, Brinkhof MW, Keiser O, Weigel R, Cornell M, Moultrie H, Prozesky H, Technau K, Eley B, Vaz P, et al. Early mortality and loss to follow-up in HIV-infected children starting antiretroviral therapy in Southern Africa. J Acquir Immune Defic Syndr 2010, 54:524-532. 10.1097/QAI.0b013e3181e0c4cf, 2925143, 20588185.
33. Witvrouw M, Pannecouque C, Switzer WM, Folks TM, De Clercq E, Heneine W. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir Ther 2004, 9:57-65.
34. Adje-Toure CA, Cheingsong R, Garcia-Lerma JG, Eholie S, Borget MY, Bouchez JM, Otten RA, Maurice C, Sassan-Morokro M, Ekpini RE, et al. Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, Cote d'Ivoire. AIDS 2003, 17(Suppl 3):S49-54.
35. Nesheim SR, Kapogiannis BG, Soe MM, Sullivan KM, Abrams E, Farley J, Palumbo P, Koenig LJ, Bulterys M. Trends in opportunistic infections in the pre- and post-highly active antiretroviral therapy eras among HIV-infected children in the Perinatal AIDS Collaborative Transmission Study, 1986-2004. Pediatrics 2007, 120:100-109. 10.1542/peds.2006-2052, 17606567.
36. Mocroft A, Kirk O, Barton SE, Dietrich M, Proenca R, Colebunders R, Pradier C, dArminio Monforte A, Ledergerber B, Lundgren JD. Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. EuroSIDA study group. AIDS 1999, 13:943-950.
37. Mannheimer S, Friedland G, Matts J, Child C, Chesney M. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis 2002, 34:1115-1121. 10.1086/339074, 11915001.
38. O'Brien DP, Sauvageot D, Zachariah R, Humblet P. In resource-limited settings good early outcomes can be achieved in children using adult fixed-dose combination antiretroviral therapy. AIDS 2006, 20:1955-1960. 10.1097/01.aids.0000247117.66585.ce, 16988517.
39. Chokephaibulkit K, Plipat N, Cressey T, Frederix K, Phongsamart W, Capparelli E, et al. Pharmacokinetics of nevirapine in HIV-infected children receiving an adult fixed-dose combination of stavudine, lamivudine and nevirapine. AIDS 2005, 19:1495-1499. 10.1097/01.aids.0000183625.97170.59, 16135903.
40. Ellis J, L'Homme R, Ewings F, et al. Nevirapine concentrations in HIV-infected children treated with divided fixed-dose combination antiretroviral tablets in Malawi and Zambia. Antivir Ther 2007, 12:253-260.